Robert S Wallis

The Aurum Institute, Johannesburg, Gauteng, South Africa

Are you Robert S Wallis?

Claim your profile

Publications (129)870.41 Total impact

  • Source
    Robert S Wallis · Thomas Peppard
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers play an essential role in accelerating drug development. Sputum culture conversion using solid medium is the best-characterized tuberculosis biomarker, having been examined at the patient and trial levels in studies with thousands of subjects, and having recently been validated using data from 3 unsuccessful phase 3 trials. We presently are poised at the threshold of regulatory innovation for antibacterials to treat drug-resistant infections, in which Special Medical Use authorization restricted to patients with limited options could be based on the results of small clinical trials. Patients worldwide would be well served by licensing of new regimens for multidrug-resistant tuberculosis based on biomarker evidence commensurate with the urgency of the current global crisis.
    Preview · Article · Sep 2015 · Clinical Infectious Diseases
  • Source

    Full-text · Dataset · Jul 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.
    Full-text · Article · Jul 2015 · Nature Reviews Drug Discovery
  • Robert S Wallis

    No preview · Article · Jun 2015 · The Lancet Respiratory Medicine
  • Source
    Robert S Wallis · Thomas Peppard · David Hermann
    [Show abstract] [Hide abstract]
    ABSTRACT: New regimens capable of shortening tuberculosis treatment without increasing the risk of recurrence are urgently needed. A 2013 meta-regression analysis, using data from trials published from 1973 to 1997 involving 7793 patients, identified 2-month sputum culture status and treatment duration as independent predictors of recurrence. The resulting model predicted that if a new 4-month regimen reduced the proportion of patients positive at month 2 to 1%, it would reduce to 10% the risk of a relapse rate >10% in a trial with 680 subjects per arm. The 1% target was far lower than anticipated. Data from the 8 arms of 3 recent unsuccessful phase 3 treatment-shortening trials of fluoroquinolone-substituted regimens (REMox, OFLOTUB, and RIFAQUIN) were used to assess and refine the accuracy of the 2013 meta-regression model. The updated model was then tested using data from a treatment shortening trial reported in 2009 by Johnson et al. The proportions of patients with recurrence as predicted by the 2013 model were highly correlated with observed proportions as reported in the literature (R2 = 0.86). Using the previously proposed threshold of 10% recurrences as the maximum likely considered acceptable by tuberculosis control programs, the original model correctly identified all 4 six-month regimens as satisfactory, and 3 of 4 four-month regimens as unsatisfactory (sensitivity = 100%, specificity = 75%, PPV = 80%, and NPV = 100%). A revision of the regression model based on the full dataset of 66 regimens and 11181 patients resulted in only minimal changes to its predictions. A test of the revised model using data from the treatment shortening trial of Johnson et al found the reported relapse rates in both arms to be consistent with predictions. Meta-regression modeling of recurrence based on month 2 culture status and regimen duration can inform the design of future phase 3 tuberculosis clinical trials.
    Preview · Article · Apr 2015 · PLoS ONE
  • Robert S Wallis · Richard Hafner
    [Show abstract] [Hide abstract]
    ABSTRACT: Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.
    No preview · Article · Mar 2015 · Nature reviews. Immunology
  • Robert S Wallis

    No preview · Article · Feb 2015 · The Lancet Respiratory Medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sutezolid (PNU-100480) is a linezolid analog with superior bactericidal activity against Mycobacterium tuberculosis in the hollow fiber, whole blood and mouse models. Like linezolid, it is unaffected by mutations conferring resistance to standard TB drugs. This study of sutezolid is its first in tuberculosis patients. Sputum smear positive tuberculosis patients were randomly assigned to sutezolid 600 mg BID (N = 25) or 1200 mg QD (N = 25), or standard 4-drug therapy (N = 9) for the first 14 days of treatment. Effects on mycobacterial burden in sputum (early bactericidal activity or EBA) were monitored as colony counts on agar and time to positivity in automated liquid culture. Bactericidal activity was also measured in ex vivo whole blood cultures (whole blood bactericidal activity or WBA) inoculated with M. tuberculosis H37Rv. All patients completed assigned treatments and began subsequent standard TB treatment according to protocol. The 90% confidence intervals (CI) for bactericidal activity in sputum over the 14 day interval excluded zero for all treatments and both monitoring methods, as did those for cumulative WBA. There were no treatment-related serious adverse events, premature discontinuations, or dose reductions due to laboratory abnormalities. There was no effect on the QT interval. Seven sutezolid-treated patients (14%) had transient, asymptomatic ALT elevations to 173±34 U/L on day 14 that subsequently normalized promptly; none met Hy's criteria for serious liver injury. The mycobactericidal activity of sutezolid 600 mg BID or 1200 mg QD was readily detected in sputum and blood. Both schedules were generally safe and well tolerated. Further studies of sutezolid in tuberculosis treatment are warranted. ClinicalTrials.gov NCT01225640.
    Full-text · Article · Apr 2014 · PLoS ONE
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis (TB) is an airborne infectious disease that kills almost 2 million individuals every year. Multidrug-resistant (MDR) TB is caused by strains of Mycobacterium tuberculosis (M. tb) resistant to isoniazid and rifampin, the backbone of first-line antitubercular treatment. MDR-TB affects an estimated 500,000 new patients annually. Genetic analysis of drug-resistant MDR-TB showed that airborne transmission of undetected and untreated strains played a major role in disease outbreaks. The need for new TB vaccines and faster diagnostics, as well as the development of new drugs, has recently been highlighted. The major problem in terms of current TB research and clinical demands is the increasing number of cases of extensively drug-resistant and ‘treatment-refractory’ TB. An emerging scenario of adjunct host-directed therapies is intended to target pulmonary TB where inflammatory processes can be deleterious and lead to immune exhaustion. ‘Target-organ saving’ strategies may be warranted to prevent damage to infected tissues and achieve focused, clinically relevant and long-lasting anti-M. tb-directed cellular immune responses. Candidates for such interventions may be biological agents or already approved drugs that can be ‘re-purposed’ to interfere with biologically relevant cellular checkpoints. Here we review current concepts of inflammation in TB disease and discuss candidate pathways for host-directed therapies in order to achieve better clinical outcomes.This article is protected by copyright. All rights reserved.
    Full-text · Article · Apr 2014 · Journal of Internal Medicine
  • Source
    Tong Zhu · Sven O Friedrich · Andreas Diacon · Robert S Wallis
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:Sutezolid (PNU-100480 or U-480) is an oxazolidinone antimicrobial being developed for treatment of tuberculosis. An active sulfoxide metabolite (PNU-101603 or U-603), which reaches concentrations in plasma several times those of the parent, has been reported to drive killing of extracellular M. tuberculosis by sutezolid in hollow fiber culture. However, the relative contributions of parent and metabolite against intracellular M. tuberculosis in vivo are not fully understood.Methods:The relationships between plasma concentrations of U-480 and U-603 and intracellular whole blood bactericidal activity (WBA) in ex vivo cultures were examined using a direct competitive population PK-PD 4 parameter sigmoid model. The dataset included 690 PK and 345 WBA determinations from 50 tuberculosis patients enrolled in a phase 2 sutezolid trial. The model parameters were solved iteratively.Results:The median U-603/U-480 concentration ratio was 7.1 (range, 1 to 28). The apparent U-603 IC50 for intracellular M. tuberculosis was 17-fold greater than U-480 (90% CI, 9.9 to 53). Model parameters were used to simulate in vivo activity after oral dosing with sutezolid 600 mg BID and 1200 mg QD. Divided dosing resulted a greater cumulative activity (-.269 log10 per day, 90% CI: -.237 to -.293) compared to single daily dosing (-.186, 90% CI: -.160 to -.208). U-480 accounted for 84% and 78% of activity for BID and QD dosing, respectively, despite the higher concentrations of U-603.Conclusions:Killing of intracellular M. tuberculosis by orally administered sutezolid is mainly due to activity of the parent compound. Taken together with other studies in the hollow fiber model, these findings suggest sutezolid and its metabolite act on different mycobacterial subpopulations.
    Preview · Article · Mar 2014 · Antimicrobial Agents and Chemotherapy
  • Source
    Robert S Wallis
    [Show abstract] [Hide abstract]
    ABSTRACT: There is increasing interest in the potential role of adjunctive anti-inflammatory therapy to accelerate tuberculosis (TB) treatment. Sputum culture conversion is an important biomarker predictor of durable TB cure. This study used meta-regression analysis to examine the relationship between corticosteroid dose and sputum culture conversion, using published data from controlled clinical trials including 1806 corticosteroid-treated TB patients. Linear models with 2 or 3 variables, including corticosteroid dose and the proportion of culture positive control subjects, predicted therapeutic benefit of corticosteroids at 1 and 2 months. The 3-variable model predicted that 134 mg of prednisolone per day, given together with standard 4-drug TB chemotherapy, would reduce the proportion of positive culture at 2 months from 15% to 2%. The estimate accounts for a 50% reduction in steroid exposure due to rifampin. A proportion of 2% of subjects with positive cultures at 2 months has been proposed as a target for new 4-month TB regimens. These positive findings must be tempered by recognition that the metabolic and cardiovascular risks of corticosteroids administered at this dose for this duration are unlikely to be acceptable when examined from a patient-level benefit-risk perspective. In future research studies to shorten TB treatment, biologic anti-inflammatory therapies with similar therapeutic effects but superior safety profiles should be considered.
    Preview · Article · Mar 2014 · Open Forum Infectious Diseases
  • Source
    Robert S Wallis

    Preview · Article · Oct 2013 · The Journal of Infectious Diseases
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the widespread use of the BCG vaccine there are more than 9 million new cases of tuberculosis (TB) every year and there is an urgent need for better TB vaccines. TB vaccine candidates are selected for evaluation based in part on the detection of an antigen-specific IFN-γ response. The measurement of mycobacterial growth in blood specimens obtained from subjects immunized with investigational TB vaccines may be a better in vitro correlate of in vivo vaccine efficacy. We performed a clinical study with 30 UK adults who were followed for 6 months to evaluate the ability of both a whole blood and a novel PBMC based mycobacterial growth inhibition assay to measure a response to primary vaccination and revaccination with BCG. Using cryopreserved PBMC we observed a significant improvement in mycobacterial growth inhibition following primary vaccination, but no improvement in growth inhibition following revaccination with BCG (p<0.05). Mycobacterial growth inhibition following primary BCG vaccination was not correlated with PPD antigen specific IFN- γ ELISPOT responses. We demonstrate that a mycobacterial growth inhibition assay can detect improved capacity to control growth following primary immunization but not revaccination with BCG. This is the first study to demonstrate that an in vitro growth inhibition assay can identify a difference in a vaccine response comparing both primary and secondary BCG vaccination, suggesting that in vitro growth inhibition assays may serve as better surrogates of clinical efficacy than those assays currently used for the assessment of candidate TB vaccines.
    Full-text · Article · Aug 2013 · Clinical and vaccine Immunology: CVI
  • Source
    Robert S Wallis · Cunshan Wang · Daniel Meyer · Neal Thomas
    [Show abstract] [Hide abstract]
    ABSTRACT: New drugs and regimens with the potential to transform tuberculosis treatment are presently in early stage clinical trials. The goal of the present study was to infer the required duration of these treatments. A meta-regression model was developed to predict relapse risk using treatment duration and month 2 sputum culture positive rate as predictors, based on published historical data from 24 studies describing 58 regimens in 7793 patients. Regimens in which rifampin was administered for the first 2 months but not subsequently were excluded. The model treated study as a random effect. The model predicted that new regimens of 4 or 5 months duration with rates of culture positivity after 2 months of 1% or 3%, would yield relapse rates of 4.0% or 4.1%, respectively. In both cases, the upper limit of the 2-sided 80% prediction interval for relapse for a hypothetical trial with 680 subjects per arm was <10%. Analysis using this model of published month 2 data for moxifloxacin-containing regimens indicated they would result in relapse rates similar to standard therapy only if administered for ≥5 months. This model is proposed to inform the required duration of treatment of new TB regimens, potentially hastening their accelerated approval by several years.
    Preview · Article · Aug 2013 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction TB vaccine studies to date have used IFN-γ as the main immunological read-out, but this may not be reliable. There is much interest in emerging functional assays which take into account a whole range of cellular mechanisms, such as in vitro Mycobacterial Growth Inhibition Assays (MGIAs). Such an assay would allow down-selection or ‘gating’ of new vaccines at an early preclinical stage, reducing long and costly clinical trials for which resources are limited. Methods We conducted a clinical study in 30 adults who received either a primary vaccination or revaccination with BCG. Volunteers attended 3 pre-vaccination visits and were followed-up for 6 months post-vaccination. We evaluated the ability of both a whole blood and a newly-developed PBMC-based in vitro MGIA to detect a vaccine-induced response. These assays utilise the Bactec MGIT system. Results Using cryopreserved PBMC we observed significant inhibition of mycobacterial growth at 4 and 8 weeks following primary BCG vaccination (p<0.05). No inhibition was observed in the group receiving BCG revaccination. There was an increase in mycobacterial growth at 24 weeks following revaccination with BCG, which correlated with a strong IFN-γ immune response at week 0, prior to revaccination (p<0.05). Mycobacterial growth inhibition also correlated with the PPD-specific IFN-γ ELISpot response at 4 weeks following revaccination (p<0.005), though overall the magnitude of the IFN-γ response did not predict ability to inhibit mycobacterial growth. Discussion and Conclusion This study suggests that a PBMC-based in vitro growth inhibition assay using the Bactec MGIT system may represent a useful tool for early screening of candidate TB vaccines. The assay detected a significant vaccine-induced response following primary vaccination, but not revaccination, with BCG. This reflects the findings of clinical efficacy trials that have been conducted using BCG. The assay also provides a platform for investigating mechanisms of immunity that mediate mycobacterial growth inhibition and protection from challenge.
    No preview · Conference Paper · Mar 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers are indispensable to the development of new tuberculosis therapeutics and vaccines. The most robust biomarkers measure factors that are essential to the underlying pathological process of the disease being treated, and thus can capture the full effects of many types of interventions on clinical outcomes in multiple prospective, randomised clinical trials. Many Mycobacterium tuberculosis and human biomarkers have been studied over the past decade. Present research focuses on three areas: biomarkers predicting treatment efficacy and cure of active tuberculosis, the reactivation of latent tuberculosis infection, and the induction of protective immune responses by vaccination. Many older, non-specific markers of inflammation, when considered in isolation, do not have sufficient predictive values for clinical use in tuberculosis. Although no new accurate, tuberculosis-specific biomarkers have yet been discovered, substantial progress has been made in some areas. However, the qualification of biomarkers as a surrogate for a clinical endpoint in tuberculosis is very challenging, and, for biomarkers that are non-culture-based, impossible to pursue without the availability of well characterised biobanks containing biospecimens from patients who have had adequate follow-up to establish long-term treatment outcome. We review progress in tuberculosis biomarker development and efforts being made to harness resources to meet future challenges.
    Full-text · Article · Mar 2013 · The Lancet Infectious Diseases
  • Robert S Wallis · Carol Nacy

    No preview · Article · Jan 2013 · The Lancet
  • Source
    Robert S Wallis
    [Show abstract] [Hide abstract]
    ABSTRACT: Six new antituberculosis compounds in 4 classes are presently in clinical trials. Although these show substantial promise for drug-resistant (DR) tuberculosis, the presently planned studies of these compounds will not inform their optimal use, as each will be tested singly vs placebo with existing drugs, rather than in new regimens. Each successive regulatory approval will increase the size, cost, and complexity of trials for those that follow, causing delays during which suboptimal use will occur and resistance will emerge. This paper proposes the development of a novel regimen with the potential for use in both drug-sensitive (DS) and DR tuberculosis. Adaptive licensing for DR tuberculosis based on 2-month sputum culture would shorten time to initial approval by several years. A global outcomes registry would confirm safety and effectiveness in both DS and DR tuberculosis, making possible the second transformation of tuberculosis treatment. We should do our utmost to see it succeed.
    Preview · Article · Oct 2012 · Clinical Infectious Diseases

  • No preview · Article · Oct 2012 · Journal of the International AIDS Society
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Novel oral regimens composed of new drugs with potent activity against Mycobacterium tuberculosis and no cross-resistance with existing agents are needed to shorten and simplify treatment for both drug-susceptible and drug-resistant tuberculosis. As part of a continuing effort to evaluate novel drug combinations for treatment-shortening potential in a murine model, we performed two long-term, relapse-based experiments. In the first experiment, several 3- and 4-drug combinations containing new agents currently in phase 2/3 trials (TMC207 [bedaquiline], PA-824 and PNU-100480 [sutezolid], and/or clofazimine) proved superior to the first-line regimen of rifampin, pyrazinamide, and isoniazid. TMC207 plus PNU-100480 was the most effective drug pair. In the second experiment, in which 3- and 4-drug combinations composed of TMC207 and pyrazinamide plus rifapentine, clofazimine, PNU-100480, or both rifapentine and clofazimine were evaluated, the rank order of drugs improving the sterilizing activity of TMC207 and pyrazinamide was as follows: rifapentine plus clofazimine ≥ clofazimine ≥ rifapentine > PNU-100480. The results revealed potential new building blocks for universally active short-course regimens for drug-resistant tuberculosis. The inclusion of pyrazinamide against susceptible isolates may shorten the duration of treatment further.
    Full-text · Article · Apr 2012 · Antimicrobial Agents and Chemotherapy

Publication Stats

6k Citations
870.41 Total Impact Points

Institutions

  • 2014-2015
    • The Aurum Institute
      Johannesburg, Gauteng, South Africa
  • 1986-2015
    • Case Western Reserve University
      • School of Medicine
      Cleveland, Ohio, United States
  • 2010-2014
    • Pfizer Inc.
      New York, New York, United States
  • 1986-2014
    • Case Western Reserve University School of Medicine
      • Department of Medicine
      Cleveland, Ohio, United States
  • 2009
    • Statens Serum Institut
      • Department of Infectious Disease Immunology
      København, Capital Region, Denmark
  • 2004-2009
    • Rutgers New Jersey Medical School
      • Department of Medicine
      Newark, New Jersey, United States
  • 2006-2008
    • PPD
      Wilmington, North Carolina, United States
  • 2004-2007
    • University of California, Los Angeles
      • • Division of Rheumatology
      • • Department of Microbiology, Immunology, and Molecular Genetics
      Los Ángeles, California, United States
  • 1998-2006
    • Harvard University
      Cambridge, Massachusetts, United States
    • Duke University
      Durham, North Carolina, United States
  • 2003
    • University of Washington Seattle
      Seattle, Washington, United States
  • 2002
    • Ewha Womans University
      Sŏul, Seoul, South Korea
  • 1997
    • Adventist University of Health Sciences
      Orlando, Florida, United States
  • 1995
    • Makerere University
      Kampala, Central Region, Uganda